KRAS and non-small cell lung carcinoma: We report the final results of the outcome of patients treated with vistusertib in treatment arm B of the National Lung Matrix Trial (NLMT), a large stratified medicine trial in NSCLC, focusing on the cohort of patients whose NSCLC harbour STK11 loss, with or without concomitant KRAS mutations.